Comparative Pharmacology
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus HARMONYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOLDOPAM MESYLATE versus HARMONYL.
FENOLDOPAM MESYLATE vs HARMONYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Harmonyl is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and blood pressure.
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
25 mg orally once daily, taken with food. Maximum dose: 50 mg once daily.
None Documented
None Documented
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal half-life: 12–18 hours (mean 15 h); extends to 24–30 h in hepatic impairment
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal: 70% as unchanged drug; Biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Antihypertensive
Antihypertensive